Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

By detailed sequence analysis and subsequent biophysical characterization of prototypic light chains, this project aims to identify sequence fingerprints in IGLV1-44 light chains leading to AL amyloidosis and POEMS syndrome. This understanding might help improve the risk stratification and early diagnosis of patients overexpressing pathologic IGLV1-44 LCs. Moreover, the development of nanobodies efficient in recognizing and stabilizing IGLV1-44 light chains which exert direct toxicity in cardiac AL amyloidosis and POEMS syndrome might form the basis for future development of therapeutic agents capable of counteracting IGLV1-44 light chain proteotoxicity.

Who May Be Eligible (Plain English)

Who May Qualify: - Biopsy-proven diagnosis of systemic AL amyloidosis, POEMS syndrome or multiple myeloma - Planned peripheral blood sampling +/- bone marrow aspiration - Age \> 18 years - Willingness to allow use of clinical data and diagnostic leftovers of clinical specimens for research purposes through signing a written willing to sign a consent form. Who Should NOT Join This Trial: - Undefined monoclonal gammopathy or non-AL amyloidosis - Patients fulfilling the criteria for complete hematologic response after anti-clonal therapy - Age \<18 years - Failure to show willingness to allow use of clinical data and diagnostic leftovers of clinical specimens for research purposes. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Biopsy-proven diagnosis of systemic AL amyloidosis, POEMS syndrome or multiple myeloma * Planned peripheral blood sampling +/- bone marrow aspiration * Age \> 18 years * Willingness to allow use of clinical data and diagnostic leftovers of clinical specimens for research purposes through signing a written informed consent. Exclusion Criteria: * Undefined monoclonal gammopathy or non-AL amyloidosis * Patients fulfilling the criteria for complete hematologic response after anti-clonal therapy * Age \<18 years * Failure to show willingness to allow use of clinical data and diagnostic leftovers of clinical specimens for research purposes.

Locations (1)

Fondazione IRCCS Policlinico San Matteo
Pavia, Italy